933 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Novo Nordisk Focuses on Pipeline Development Amid Competition http://www.zacks.com/stock/news/552953/novo-nordisk-focuses-on-pipeline-development-amid-competition?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-552953 Oct 07, 2019 - Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY http://www.zacks.com/stock/news/549246/pharma-stock-roundup-jnjs-opioid-settlement-fda-updates-for-azn-gsk-mrk-rhhby?cid=CS-ZC-FT-analyst_blog|stock_roundup-549246 Oct 04, 2019 - J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion http://www.zacks.com/stock/news/549197/gileads-descovy-hiv-regimen-gets-fda-nod-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-549197 Oct 04, 2019 - Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
Merck's Pediatric Filings for Dificid Get FDA's Priority Review http://www.zacks.com/stock/news/547611/mercks-pediatric-filings-for-dificid-get-fdas-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-547611 Oct 03, 2019 - The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/545810/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-545810 Oct 02, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA http://www.zacks.com/stock/news/545656/astrazenecas-triple-combo-copd-inhaler-gets-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-545656 Oct 02, 2019 - AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.
Immunomedics (IMMU) Reports Interim Urothelial Cancer Data http://www.zacks.com/stock/news/544876/immunomedics-immu-reports-interim-urothelial-cancer-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-544876 Oct 01, 2019 - Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.
Seattle Genetics Up on Positive Data From Bladder Cancer Study http://www.zacks.com/stock/news/544569/seattle-genetics-up-on-positive-data-from-bladder-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-544569 Oct 01, 2019 - Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.
Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study http://www.zacks.com/stock/news/542861/glaxos-zejula-betters-pfs-in-first-line-ovarian-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542861 Sep 30, 2019 - Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.
AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study http://www.zacks.com/stock/news/542841/astrazeneca-mercks-lynparza-improves-pfs-in-frontline-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542841 Sep 30, 2019 - AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.

Pages: 123456789...94

<<<Page 4>